Table 4.

Tumor characteristics associated with statin use

Tumor characteristicsStatin use ≥2 yStatin use “Never”OR (95% CI)a
ER status
 ER+1,588 (10.1)14,134 (89.9)Reference
 ER−262 (7.3)3,330 (92.7)0.90 (0.78–1.04)
PR status
 PR+1,276 (10.0)11,496 (90.0)Reference
 PR−564 (8.7)5,910 (91.3)0.92 (0.82–1.03)
HER2 statusb
 HER2−1,042 (15.7)5,579 (84.3)Reference
 HER2+247 (12.8)1,684 (87.2)0.94 (0.80–1.10)
Intrinsic subtypeb
 Luminal A931 (16.4)4,728 (83.5)Reference
 Luminal B176 (12.9)1,185 (87.1)0.96 (0.88–1.05)
 HER2+/ER−70 (12.3)498 (87.7)0.95 (0.83–1.10)
 Triple-negative111 (11.5)851 (88.5)0.92 (0.82–1.03)
Tumor stage
 Localized1,298 (10.2)11,377 (89.8)Reference
 Regional483 (8.2)5,410 (91.8)0.99 (0.94–1.05)
 Metastasis59 (9.7)550 (90.3)1.01(0.87–1.17)
Tumor grade
 Grade I452 (11.0)3,652 (89.0)Reference
 Grade II761 (10.2)6,711 (89.8)1.02 (0.95–1.09)
 Grade III392 (7.7)4,686 (92.3)0.99 (0.92–1.06)
  • aOR adjusted for age, prescription drug coverage, oral contraceptive use, hormone therapy use, and race.

  • bHER2 status was only evaluated in tumors 2002 to 2007.